coronavirus Archives - Page 5 of 84 -

People with long-lasting symptoms of breathlessness after COVID-19 infection may have damage to their lungs that does not

New diagnostic finds hidden lung damage in long COVID

https://pharmaphorum.com/news/new-diagnostic-finds-hidden-lung-damage-in-long-covid/

News/ News/ R&D

Daiichi makes play for share of Japan’s COVID booster market

Phil Taylor coronavirus, COVID-19, COVID-19 vaccine, Daiichi Sankyo, Japan, Omicron 0 Comment

Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new

Daiichi makes play for share of Japan’s COVID booster market

https://pharmaphorum.com/news/daiichi-makes-play-for-share-of-japans-covid-booster-market/

News/ News/ R&D

Moderna starts dosing patients with its Omicron COVID jab

Phil Taylor coronavirus, COVID-19, COVID-19 vaccine, Moderna, Omicron 0 Comment

Moderna has started human trials of an Omicron version of its COVID-19 vaccine SpikeVax, just in case a

Moderna starts dosing patients with its Omicron COVID jab

https://pharmaphorum.com/news/moderna-starts-dosing-patients-with-its-omicron-covid-jab/

News/ News/ R&D

Pfizer starts dosing patients with its Omicron COVID shot

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Omicron, Pfizer 0 Comment

Pfizer and partner BioNTech have started their clinical trial of a new version of their COVID-19 vaccine that

Pfizer starts dosing patients with its Omicron COVID shot

https://pharmaphorum.com/news/pfizer-starts-dosing-patients-with-its-omicron-covid-shot/

News/ News/ Sales and Marketing

FDA bans use of Lilly, Regeneron COVID drugs due to Omicron

Phil Taylor antibody, coronavirus, COVID-19, Eli Lilly, Regeneron, Sales and Marketing 0 Comment

The FDA has limited the use of COVID-19 antibody therapies developed by Eli Lilly and Regeneron, on the

FDA bans use of Lilly, Regeneron COVID drugs due to Omicron

https://pharmaphorum.com/news/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron/

COVID-19 lessons for how pharma should support patient advocacy

News/ News/ Patients

Should we be worried about Omicron ‘stealth variant’ BA.2?

Phil Taylor coronavirus, COVID-19, Omicron, variant 0 Comment

With healthcare systems around the world labouring under the strain of dealing with the Omicron wave of COVID-19

Should we be worried about Omicron ‘stealth variant’ BA.2?

https://pharmaphorum.com/news/should-we-be-worried-about-omicron-stealth-variant-ba-2/

News/ News/ Sales and Marketing

FDA clears Gilead’s Veklury for COVID outpatients

Phil Taylor antiviral, coronavirus, COVID-19, fda, Gilead Sciences, NIH, Veklury 0 Comment

The FDA has extended the emergency use authorisation for Gilead Sciences’ antiviral Veklury to include non-hospitalised patients with

FDA clears Gilead’s Veklury for COVID outpatients

https://pharmaphorum.com/news/fda-clears-gileads-veklury-for-covid-outpatients/

News/ News/ R&D

Covid vaccine booster raises antibody levels in fight against Omicron

Joy Persaud clinical trials, coronavirus, COVID-19, Omicron, pharma, R&D, vaccine 0 Comment

A third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to

Covid vaccine booster raises antibody levels in fight against Omicron

https://pharmaphorum.com/news/covid-vaccine-booster-raises-antibody-levels-in-fight-against-omicron/

Market Access/ News/ News

Poolbeg licences candidate for broad-spectrum respiratory infections

Joy Persaud coronavirus, infectious disease, influenza, pharma, Poolbeg Pharma, viruses 0 Comment

Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections,

Poolbeg licences candidate for broad-spectrum respiratory infections

https://pharmaphorum.com/news/poolbeg-licences-candidate-for-broad-spectrum-respiratory-infections/

Trending

coronavirus

Login